Company History

2022 

October         

  • Invited to exhibit in “Taiwan Innotech Expo"

  • Invited to participate in 2022 TREE matchmaking, DOIT, MOEA

September

  • Invited to participate in the business activity of Lithuanian Ministry of Economy and Innovation delegation

June

  • Invited to participate in the business activity of Lithuanian Ministry of Economy and Innovation delegation

February     

  • MOEA agreed to exclusive authorization of 45 patents for 7 families and for 28 countries to BELX

January

  • Listed in Taiwan Tech Arena Best 100 and participated in CES 2022 with TTA

 

2021 

November  

  • Initiated long-term toxicology testing Obtained the trademark registration right of "BELX®" in China

October

  • Awarded the 3rd Place of Taiwan Research-Institute Entrepreneur, DOIT, MOEA

August           

  • Selected to participate in 2021 SelectUSA Investment Summit
  • Selected to participate in 2021 FINDIT speed dating matchmaking
  • Awarded Judges’ Choice from Taiwan Research-Institute Entrepreneur Ecosystem Program, DOIT, MOEA

May     

  • Obtained the trademark registration right of "BELX®" in Taiwan

  • Successfully technology transferred the GACP plantation from Council of Agriculture, Executive Yuan

March    

  • Patent application for structures of major active ingredients

February

  • Obtained the trademark registration right of "BELX®" in HongKong

 

2020 

December          

  • Awarded Best Startup from ITIC, ITRI

September          

  • Completed A+ Industrial Innovative R&D Program - Fast Track Clinical Trial Project of the Department of Industrial Technology (DOIT) approved by MOEA

July

  • Awarded for the 4th G Camp Growing Global Go, Small and Medium Enterprise Administration, MOEA

June

  • TAF testing laboratory (3607) passed the ISO 17025 annual supervision and evaluation

  • Selected to participate in the 2020 BIO DIGITAL (North America)

April                     

  • Cooperated with Council of Agriculture, Executive Yuan to carry out the medicinal material GACP plantation

  • Completed phase I clinical trial of botanical new drug BEL-X

 

2019

December 

  • Global Top 100 Science and Technology Innovation Competition - Taiwan Session, 3rd place awarded.

  • TAF testing laboratory (3607) ISO17025 accredited.

October

  • Completed Project of Subsidies & Incentives for Taipei, Industry Department of Economic Development, Taipei City Government

November

  • Redefining Early-Stage Investment (RESI) Innovation Challenge - Taipei Session, selected for pitch.

  • Funding support for Small Business Innovation R & D Program (SBIR) by Small and Medium Enterprise Administration, MOEA

September

  • China BioMed Innovation and Investment Conference (CBIIC), selected for roadshow.

  

2018

November

  • Approved as a biotech new drug development company by MOEA

  • Dr. Shau-feng Chang, CEO, wins MOEA’s Seventh Female Entrepreneurship Elite Competition - New Venture Group - Science and Technology Innovation award.

October

  • Small Business Innovation R & D Program (SBIR) approved by the Small Business Division of MOEA with funding support

September

  • Funding support by Taipei Industrial Development R & D Subsidy Program of the Bureau of Economy of Taipei City Government

January

  • A+ Industrial Innovative R&D Program - Fast Track Clinical Trial Project of the Department of Industrial Technology (DOIT) approved by MOEA with funding support

 

2017 

November

  • Approval for establishment of park branch company by the Hsinchu Science and Technology Industrial Park of the Ministry of Science and Technology.

July

  • Recruitment of phase 1 clinical trial for botanical new drug BEL-X started.

May

  • Phase I clinical trial application (IND) of botanical new drug BEL-X approved by TFAD

February

  • Phase I clinical trial application of botanical new drug BEL-X approved by the NTUH IRB

January

  • Phase I clinical trial application of botanical new drug BEL-X approved by the NCKUH IRB

  

2016

September

  • Signed exclusive technology transfer agreement with ITRI

May

  • Stationed in the Incubation Center on ITRI Chung-Hsing Campus.

March

  • BELX Bio-pharmaceutical (Taiwan) Corporation established

 

2015

December

  • Phase I clinical trial application (IND) of botanical new drug BEL-X approved by the US FDA

 

2000~2014(In ITRI) 

2014-2015

  • Preparation for Clinical Trials of Botanical New Drug BEL-X initiated by ITRI

2001-2013

  • Collaboration with National Taiwan University Hospital in Hepatitis B and liver cancer efficacy studies

2009-2012

  • Liver Cancer and Anti-Inflammatory Chinese Herbal Medicine Program funded by MOEA

2005-2008

  • Development of new anti-viral and anti-inflammatory Chinese herbal medicines and establishment of modern technology platform funded by MOEA

2000-2004

  • Development of New Chinese Medicine for Liver Diseases and Asthma funded by the Ministry of Economic Affairs (MOEA)

 

 

 

 kite